PROTAC / Degrader Phase 1 Licensing Benchmarks
Deal economics across 7 transactions with 7 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$96M
7 deals with terms
Median Total Value
$832M
Upfront + milestones
Royalty Range
6.3%--17%
Average low--high
Deal Count
7
2020--2024
The median upfront payment for phase 1 protac / degrader licensing deals is $96M, based on 7 deals with disclosed terms from 2020--2024. Total deal values (including milestones) reach a median of $832M. Royalty rates typically range from 6.3% to 17%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Arvinas | Pfizer | 2021 | $650M | $2.0B |
| Arvinas | Novartis | 2022 | $150M | $1.2B |
| Kymera Therapeutics | Sanofi | 2023 | $150M | $2.0B |
Showing 3 of 7 deals with disclosed terms. Full comp set available in the report.
Full protac phase-1 Comp Set
Get the complete analysis -- 7 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific protac / degrader asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2020--2024). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.